| | | | | | | | | | | | | | | | |
| | |
 | Issue Date FY: 2026 ( Subtotal = $15,313,156 ) (Continued on the next page) |
| | 2026 | 2026 | CHILDREN'S HOSPITAL CORPORATION, THE | 300 LONGWOOD AVE | BOSTON | MA | 02115-5724 | SUFFOLK | USA | R01HD112379 | Metabolic control of the neural crest epigenome | 000 | 3 | NIH | 12/15/2025 | $504,496 |
| | 2026 | 2026 | CHILDREN'S HOSPITAL CORPORATION, THE | 300 LONGWOOD AVE | BOSTON | MA | 02115-5724 | SUFFOLK | USA | R01AR083424 | T peripheral regulatory cells as modulators of T cell-B cell interactions in arthritis | 000 | 3 | NIH | 12/10/2025 | $463,780 |
| | 2026 | 2026 | CHILDREN'S HOSPITAL CORPORATION, THE | 300 LONGWOOD AVE | BOSTON | MA | 02115-5724 | SUFFOLK | USA | R01AI065617 | Genetic and Epigenetic Programming of Allergic Airway Inflammation | 000 | 25 | NIH | 12/30/2025 | $671,801 |
| | 2026 | 2026 | CHILDREN'S HOSPITAL CORPORATION, THE | 300 LONGWOOD AVE | BOSTON | MA | 02115-5724 | SUFFOLK | USA | R01AI126915 | Immunological and Microbial Mechanisms in Food Allergy | 000 | 9 | NIH | 12/30/2025 | $627,598 |
| | 2026 | 2026 | CHILDREN'S HOSPITAL CORPORATION, THE | 300 LONGWOOD AVE | BOSTON | MA | 02115-5724 | SUFFOLK | USA | K23HD113884 | Social Risk Screening and Referral Implementation for All Pediatric Hospitals – The SOCIAL-H Study | 000 | 2 | NIH | 12/23/2025 | $75,000 |
| | 2026 | 2026 | CHILDREN'S HOSPITAL CORPORATION, THE | 300 LONGWOOD AVE | BOSTON | MA | 02115-5724 | SUFFOLK | USA | K23HD113884 | Social Risk Screening and Referral Implementation for All Pediatric Hospitals – The SOCIAL-H Study | 000 | 2 | NIH | 12/23/2025 | $81,033 |
| | 2026 | 2026 | CHILDREN'S HOSPITAL CORPORATION, THE | 300 LONGWOOD AVE | BOSTON | MA | 02115-5724 | SUFFOLK | USA | K00NS120596 | The Development of Facial Motor Neuron Subtypes in Health and in Congenital Facial Weakness | 000 | 6 | NIH | 12/17/2025 | $100,588 |
| | 2026 | 2026 | CHILDREN'S HOSPITAL CORPORATION, THE | 300 LONGWOOD AVE | BOSTON | MA | 02115-5724 | SUFFOLK | USA | F32AI189235 | Antiretroviral mechanisms of TRIM56 | 000 | 2 | NIH | 12/10/2025 | $81,040 |
| | 2026 | 2026 | CHILDREN'S HOSPITAL CORPORATION, THE | 300 LONGWOOD AVE | BOSTON | MA | 02115-5724 | SUFFOLK | USA | F32AI186297 | Understanding the role of transmembrane proteins for Plasmodium cell division | 000 | 2 | NIH | 12/2/2025 | $75,520 |
| | 2026 | 2026 | CHILDREN'S HOSPITAL CORPORATION, THE | 300 LONGWOOD AVE | BOSTON | MA | 02115-5724 | SUFFOLK | USA | T2331594 | Children's Hospitals Graduate Medical Education Payment Program | 09 | 8 | HRSA | 12/1/2025 | $1,784,880 |
| | 2026 | 2026 | CHILDREN'S HOSPITAL CORPORATION, THE | 300 LONGWOOD AVE | BOSTON | MA | 02115-5724 | SUFFOLK | USA | T2331594 | Children's Hospitals Graduate Medical Education Payment Program | 09 | 8 | HRSA | 12/1/2025 | $3,990,056 |
| | 2026 | 2026 | CHILDREN'S HOSPITAL CORPORATION, THE | 300 LONGWOOD AVE | BOSTON | MA | 02115-5724 | SUFFOLK | USA | R01NS140165 | Use-Dependent Adjustments to Dopamine Reception in Motivational Control | 000 | 2 | NIH | 12/12/2025 | $483,169 |
| | 2026 | 2026 | CHILDREN'S HOSPITAL CORPORATION, THE | 300 LONGWOOD AVE | BOSTON | MA | 02115-5724 | SUFFOLK | USA | R21CA296527 | Advanced Genetic Engineering to Unravel Tumor-Specific B Cell Responses | 000 | 2 | NIH | 12/16/2025 | $187,235 |
| | 2026 | 2026 | CHILDREN'S HOSPITAL CORPORATION, THE | 300 LONGWOOD AVE | BOSTON | MA | 02115-5724 | SUFFOLK | USA | R21AI178693 | Candida albicans Target of Rapamycin in oxidative stress responses | 000 | 2 | NIH | 11/26/2025 | $222,500 |
| | 2026 | 2026 | CHILDREN'S HOSPITAL CORPORATION, THE | 300 LONGWOOD AVE | BOSTON | MA | 02115-5724 | SUFFOLK | USA | R01NS124879 | Developmentally Programmed Remodeling of Apical ECM | 000 | 5 | NIH | 12/15/2025 | $393,522 |
| | 2026 | 2026 | CHILDREN'S HOSPITAL CORPORATION, THE | 300 LONGWOOD AVE | BOSTON | MA | 02115-5724 | SUFFOLK | USA | R01NS121657 | Motion and Distortion Robust Diffusion Weighted Imaging Sequences for Pediatric Patients | 000 | 4 | NIH | 12/17/2025 | $398,250 |
| | 2026 | 2026 | CHILDREN'S HOSPITAL CORPORATION, THE | 300 LONGWOOD AVE | BOSTON | MA | 02115-5724 | SUFFOLK | USA | R01NS120986 | Predicting ASD and Other Developmental Outcomes in the First Year of Life Using EEG in a Diverse Community-Based Sample | 000 | 5 | NIH | 12/12/2025 | $1,138,899 |
| | 2026 | 2026 | CHILDREN'S HOSPITAL CORPORATION, THE | 300 LONGWOOD AVE | BOSTON | MA | 02115-5724 | SUFFOLK | USA | R01NS121334 | Fetal Brain MRI as a Predictor of Late Neurodevelopmental Outcome in Congenital Heart Disease | 000 | 5 | NIH | 12/24/2025 | $396,666 |
| | 2026 | 2026 | CHILDREN'S HOSPITAL CORPORATION, THE | 300 LONGWOOD AVE | BOSTON | MA | 02115-5724 | SUFFOLK | USA | R01MH137477 | Longitudinal EEG and Environmental Trajectories Leading to ADHD and Disruptive Behaviors from Infancy to Preschool | 000 | 2 | NIH | 12/12/2025 | $788,385 |
| | 2026 | 2026 | CHILDREN'S HOSPITAL CORPORATION, THE | 300 LONGWOOD AVE | BOSTON | MA | 02115-5724 | SUFFOLK | USA | R01NS112343 | Development of Specific Neuron-Glia Attachments | 000 | 7 | NIH | 12/19/2025 | $522,803 |
| | 2026 | 2026 | CHILDREN'S HOSPITAL CORPORATION, THE | 300 LONGWOOD AVE | BOSTON | MA | 02115-5724 | SUFFOLK | USA | R01MH111647 | How do neurons in the brain decide to refine their synaptic connections in vivo? | 000 | 9 | NIH | 12/17/2025 | $869,580 |
| | 2026 | 2026 | CHILDREN'S HOSPITAL CORPORATION, THE | 300 LONGWOOD AVE | BOSTON | MA | 02115-5724 | SUFFOLK | USA | R01AR080079 | Epigenetic dysregulation of muscle differentiation in Kabuki syndrome | 000 | 5 | NIH | 12/24/2025 | $477,031 |
| | 2026 | 2026 | CHILDREN'S HOSPITAL CORPORATION, THE | 300 LONGWOOD AVE | BOSTON | MA | 02115-5724 | SUFFOLK | USA | R01GM148392 | CD11c as a novel target to improve neutrophil effector functions and sepsis outcome | 000 | 4 | NIH | 12/17/2025 | $342,451 |
| | 2026 | 2025 | CHILDREN'S HOSPITAL CORPORATION, THE | 300 LONGWOOD AVE | BOSTON | MA | 02115-5724 | SUFFOLK | USA | R01EB032708 | Fetal MRI: robust self-driving brain acquisition and body movement quantification | 000 | 4 | NIH | 10/14/2025 | $0 |
| | 2026 | 2025 | CHILDREN'S HOSPITAL CORPORATION, THE | 300 LONGWOOD AVE | BOSTON | MA | 02115-5724 | SUFFOLK | USA | R01DK125561 | Robust quantitative MR imaging markers of response to therapy in Crohn’s Disease | 000 | 5 | NIH | 11/25/2025 | $0 |
| | 2026 | 2025 | CHILDREN'S HOSPITAL CORPORATION, THE | 300 LONGWOOD AVE | BOSTON | MA | 02115-5724 | SUFFOLK | USA | R01CA196703 | Mechanisms of resistance to ALK inhibitors in ALK-rearranged lymphoma | 000 | 10 | NIH | 12/5/2025 | $0 |
| | 2026 | 2025 | CHILDREN'S HOSPITAL CORPORATION, THE | 300 LONGWOOD AVE | BOSTON | MA | 02115-5724 | SUFFOLK | USA | K23DK127251 | Effect of Thickened Feeds on Swallow Physiology and Clinical Outcomes in Children with Brief Resolved Unexplained Event | 000 | 5 | NIH | 12/4/2025 | $0 |
| | 2026 | 2025 | CHILDREN'S HOSPITAL CORPORATION, THE | 300 LONGWOOD AVE | BOSTON | MA | 02115-5724 | SUFFOLK | USA | F32MD017452 | Sexual Minority Mental Health During the COVID-19 Pandemic: An Intersectional, Social Epidemiologic Investigation | 000 | 3 | NIH | 12/5/2025 | $0 |
| | 2026 | 2025 | CHILDREN'S HOSPITAL CORPORATION, THE | 300 LONGWOOD AVE | BOSTON | MA | 02115-5724 | SUFFOLK | USA | H1754797 | Healthy Tomorrows Partnership for Children Program | 02 | 1 | HRSA | 11/20/2025 | $0 |
| | 2026 | 2025 | CHILDREN'S HOSPITAL CORPORATION, THE | 300 LONGWOOD AVE | BOSTON | MA | 02115-5724 | SUFFOLK | USA | U19AI158076 | Attacking failure of antibiotic treatment by targeting antimicrobial resistance enabler cell-states | 000 | 4 | NIH | 12/29/2025 | $0 |
| | 2026 | 2025 | CHILDREN'S HOSPITAL CORPORATION, THE | 300 LONGWOOD AVE | BOSTON | MA | 02115-5724 | SUFFOLK | USA | U19AI189176 | Immunization against Multidrug-resistant Pathogens: Activating T Cell Immunity (IMPACT-CETR) | 000 | 1 | NIH | 11/28/2025 | $0 |
| | 2026 | 2025 | CHILDREN'S HOSPITAL CORPORATION, THE | 300 LONGWOOD AVE | BOSTON | MA | 02115-5724 | SUFFOLK | USA | U01DD001266 | COMP B-NATIONAL SB PATIENT REGISTRY AT THE BOSTON CHILDRENS HOSPITAL | 04 | 5 | CDC | 11/17/2025 | $0 |
| | 2026 | 2025 | CHILDREN'S HOSPITAL CORPORATION, THE | 300 LONGWOOD AVE | BOSTON | MA | 02115-5724 | SUFFOLK | USA | R33HL164373 | Multi-center, randomized, controlled trial of the feasibility and safety of inhaled hydrogen gas during ECPR | 000 | 4 | NIH | 11/27/2025 | $0 |
| | 2026 | 2025 | CHILDREN'S HOSPITAL CORPORATION, THE | 300 LONGWOOD AVE | BOSTON | MA | 02115-5724 | SUFFOLK | USA | R56HD119040 | Trends and Epidemiology through Real-time Injury Surveillance (TETRIS): Novel Use of Physician-Informed Natural Language Processing in Emergency Department Data for Pediatric Injury Surveillance | 000 | 1 | NIH | 11/19/2025 | $0 |
| | 2026 | 2025 | CHILDREN'S HOSPITAL CORPORATION, THE | 300 LONGWOOD AVE | BOSTON | MA | 02115-5724 | SUFFOLK | USA | R35GM146974 | Digital data streams and machine learning for real-time modeling of vaccine-preventable infectious diseases | 000 | 4 | NIH | 12/2/2025 | $0 |
| | 2026 | 2025 | CHILDREN'S HOSPITAL CORPORATION, THE | 300 LONGWOOD AVE | BOSTON | MA | 02115-5724 | SUFFOLK | USA | R21CA283420 | Engineered exosome mimetics as targeted biological nanomedicines for pancreatic cancer | 000 | 2 | NIH | 12/2/2025 | $0 |
| | 2026 | 2025 | CHILDREN'S HOSPITAL CORPORATION, THE | 300 LONGWOOD AVE | BOSTON | MA | 02115-5724 | SUFFOLK | USA | R01HL181969 | Optimizing HCT Outcomes: A Multi-omic Investigation | 000 | 1 | NIH | 12/3/2025 | $0 |
| | 2026 | 2025 | CHILDREN'S HOSPITAL CORPORATION, THE | 300 LONGWOOD AVE | BOSTON | MA | 02115-5724 | SUFFOLK | USA | R01HL152358 | Exploring the relationship between advanced multimodal brain MRI phenotypes, genes and cognitive outcome in adults with CHD | 000 | 5 | NIH | 12/5/2025 | $0 |
| | 2026 | 2025 | CHILDREN'S HOSPITAL CORPORATION, THE | 300 LONGWOOD AVE | BOSTON | MA | 02115-5724 | SUFFOLK | USA | R01HL150106 | Pericytes differentiate into smooth muscle cells through HIF2a/SDF1 activation | 000 | 5 | NIH | 10/29/2025 | $0 |
| | 2026 | 2025 | CHILDREN'S HOSPITAL CORPORATION, THE | 300 LONGWOOD AVE | BOSTON | MA | 02115-5724 | SUFFOLK | USA | R01HD119283 | Neuroendocrine computations underlying an enduring behavioral state | 000 | 1 | NIH | 11/19/2025 | $0 |
| | 2026 | 2025 | CHILDREN'S HOSPITAL CORPORATION, THE | 300 LONGWOOD AVE | BOSTON | MA | 02115-5724 | SUFFOLK | USA | R01HD114338 | Developing novel MR tools to optimize surgical planning and fetal outcome in TTTS | 000 | 2 | NIH | 12/9/2025 | $0 |
| | 2026 | 2025 | CHILDREN'S HOSPITAL CORPORATION, THE | 300 LONGWOOD AVE | BOSTON | MA | 02115-5724 | SUFFOLK | USA | R01FD008498 | Antisense oligonucleotide treatment of Ataxia-Telangiectasia IND#144349 IND/IDE April 19, 2024 | 000 | 1 | FDA | 11/20/2025 | $0 |
| | 2026 | 2025 | CHILDREN'S HOSPITAL CORPORATION, THE | 300 LONGWOOD AVE | BOSTON | MA | 02115-5724 | SUFFOLK | USA | R01FD008498 | Antisense oligonucleotide treatment of Ataxia-Telangiectasia IND#144349 IND/IDE April 19, 2024 | 000 | 1 | FDA | 11/20/2025 | $0 |
| | 2026 | 2025 | CHILDREN'S HOSPITAL CORPORATION, THE | 300 LONGWOOD AVE | BOSTON | MA | 02115-5724 | SUFFOLK | USA | R01ES034713 | Interdisciplinary approaches for understanding how arsenic and micronutrients affect the epigenome to influence spina bifida risk | 000 | 3 | NIH | 11/11/2025 | $0 |
| | 2026 | 2024 | CHILDREN'S HOSPITAL CORPORATION, THE | 300 LONGWOOD AVE | BOSTON | MA | 02115-5724 | SUFFOLK | USA | R01AI154653 | Molecular mechanisms for antiviral signaling and regulation by MDA5 and TRIM65 | 000 | 5 | NIH | 12/19/2025 | $0 |
| | 2026 | 2024 | CHILDREN'S HOSPITAL CORPORATION, THE | 300 LONGWOOD AVE | BOSTON | MA | 02115-5724 | SUFFOLK | USA | K23HL148312 | Epinephrine in the Pediatric Intensive Care Unit: A Dose-Effect Trial | 000 | 5 | NIH | 12/23/2025 | $0 |
| | 2026 | 2024 | CHILDREN'S HOSPITAL CORPORATION, THE | 300 LONGWOOD AVE | BOSTON | MA | 02115-5724 | SUFFOLK | USA | K00CA253749 | Characterizing Chromatin Remodeling Mechanisms of Chemo-Sensitivity and Resistance in Pediatric Solid Tumors | 000 | 5 | NIH | 11/25/2025 | $0 |
| | 2026 | 2024 | CHILDREN'S HOSPITAL CORPORATION, THE | 300 LONGWOOD AVE | BOSTON | MA | 02115-5724 | SUFFOLK | USA | UH3TR003279 | Tissue chips for precision treatment of catecholaminergic polymorphic ventricular tachycardia | 000 | 5 | NIH | 12/12/2025 | -$327,138 |
| | 2026 | 2024 | CHILDREN'S HOSPITAL CORPORATION, THE | 300 LONGWOOD AVE | BOSTON | MA | 02115-5724 | SUFFOLK | USA | UH3TR003279 | Tissue chips for precision treatment of catecholaminergic polymorphic ventricular tachycardia | 000 | 5 | NIH | 12/12/2025 | -$7,548 |
|
